An emollient PLUS balm is useful for the management of xerosis in cancer-treated patients: a real-world, prospective, observational, multicenter study

Véronique Vendrely¹ (Pr), Ander Mayor-Ibarguren² (Dr, MD), Aline Stennevin³ and Ariadna Ortiz-Brugués³ (MD, PhD)

¹ Pôle radiothérapie, CHU Haut Lévêque, 33318 Pessac, France
² Department of Dermatology and Venereology, La Paz Hospital, 28046 Madrid, Spain
³ Laboratoires Dermatologiques Avène, Pierre Fabre Dermo-Cosmétique, 81500 Lavaur, France

Corresponding author:

Ariadna Ortiz-Brugués, Laboratoires Dermatologiques Avène, Pierre Fabre Dermo-Cosmétique, Les Cauquillous, 81500 Lavaur, France.

E-mail: ariadna.ortiz@pierre-fabre.com
### SUPPLEMENTARY TABLES

Table S1: Data on the changes in xerosis grade between baseline and follow-up, and on the overall effectiveness, tolerance and clinical success at the study end in the whole population and according to anticancer treatment.

| Xerosis grade, N (%) | Whole population N=292 | Chemotherapy N=105 | Targeted therapy N=100 | Hormonotherapy N=19 | Radiotherapy N=20 | Combined therapy N=48 |
|---------------------|-------------------------|--------------------|------------------------|---------------------|-------------------|----------------------|
| Improved            | 183 (62.7)              | 61 (58.1)          | 73 (73.0)              | 17 (89.5)           | 4 (20.0)          | 28 (58.3)            |
| Not changed         | 101 (34.6)              | 40 (38.1)          | 27 (27.0)              | 2 (10.5)            | 15 (75.0)         | 17 (35.4)            |
| Worsened            | 8 (2.7)                 | 4 (3.8)            | 0 (0)                  | 0 (0)               | 1 (5.0)           | 3 (6.3)              |

| Overall effectiveness rated by the physician, N (%) | N=316 | N=110 | N=106 | N=19 | N=29 | N=52 |
|-----------------------------------------------------|-------|-------|-------|------|------|------|
| Very effective                                     | 166   | 53    | 60    | 17   | 14   | 22   |
| Effective                                           | 112   | 41    | 34    | 1    | 13   | 23   |
| Moderately effective                               | 37    | 16    | 11    | 1    | 2    | 7    |
| Not effective                                      | 1     | 0     | 1     | 0    | 0    | 0    |

| Overall effectiveness rated by the patient, N (%) | N=314 | N=107 | N=106 | N=19 | N=30 | N=52 |
|----------------------------------------------------|-------|-------|-------|------|------|------|
| Very effective                                     | 153   | 49    | 48    | 13   | 18   | 25   |
| Effective                                           | 121   | 40    | 46    | 5    | 9    | 21   |
| Moderately effective                               | 38    | 18    | 10    | 1    | 3    | 6    |
| Not effective                                      | 2     | 0     | 2     | 0    | 0    | 0    |

| Tolerance, N (%) | N=317 | N=111 | N=106 | N=19 | N=29 | N=52 |
|------------------|-------|-------|-------|------|------|------|
| Very good        | 253   | 90    | 79    | 18   | 22   | 44   |
| Good             | 55    | 18    | 23    | 1    | 6    | 7    |
| Poor             | 7     | 3     | 2     | 0    | 1    | 1    |
| Very poor        | 2     | 0     | 2     | 0    | 0    | 0    |

| Clinical success *, N (%) | N=319 | N=111 | N=106 | N=19 | N=30 | N=53 |
|---------------------------|-------|-------|-------|------|------|------|
| Success                   | 235   | 76    | 84    | 18   | 18   | 39   |
| Failure                   | 84    | 35    | 22    | 1    | 12   | 14   |

Abbreviations: N, Total number of patients for whom data were collected. * Overall clinical success was defined according to the combination of the following criteria: ≥10% improvement in the total score for objective clinical signs and for subjective clinical signs; ≥20% improvement in the DLQI score; and global effectiveness assessed by the physician or by the patient as “very effective” or “effective”, or tolerance assessed by the physician as “very good” or “good”.
Table S2: Absolute changes in severity scores for clinical symptoms and in patient quality of life scores between baseline and follow-up in the whole population and according to anticancer treatment.

| Objective Clinical Symptoms | Whole Population | Chemotherapy | Targeted Therapy | Hormone Therapy | Radiotherapy | Combined Therapy |
|-----------------------------|------------------|--------------|------------------|----------------|--------------|-----------------|
| Sevity score, mean (SD)     | N=314            | N=109        | N=104            | N=19           | N=30         | N=52            |
| Xerosis                     | -1.1 (0.8)       | -1.2 (0.7)   | -1.2 (0.7)       | -1.5 (0.5)     | -0.2 (0.4)   | -1.0 (1.0)      |
| Desquamation                | -0.9 (0.9)       | -0.9 (0.8)   | -1.2 (0.7)       | -1.2 (0.7)     | -0.1 (0.6)   | -0.8 (1.1)      |
| Erythema                    | -0.6 (0.9)       | -0.6 (0.8)   | -0.8 (0.8)       | -0.8 (0.7)     | -0.1 (0.7)   | -0.5 (1.0)      |
| Total score                 | -2.6 (2.0)       | -2.7 (1.8)   | -3.2 (1.6)       | -3.5 (1.2)     | -0.4 (1.4)   | -2.3 (2.7)      |

| Subjective Clinical Symptoms | Whole Population | Chemotherapy | Targeted Therapy | Hormone Therapy | Radiotherapy | Combined Therapy |
|------------------------------|------------------|--------------|------------------|----------------|--------------|-----------------|
| VAS score, mean (SD)         | N=316            | N=110        | N=106            | N=19           | N=29         | N=52            |
| Sleep disturbance            | -1.4 (2.2)       | -1.2 (2.0)   | -1.7 (2.3)       | -1.7 (2.1)     | -0.6 (1.8)   | -1.6 (2.4)      |
| Pruritus                     | -2.5 (2.6)       | -2.3 (2.3)   | -3.1 (2.5)       | -4.3 (2.1)     | 0.0 (2.1)    | -2.4 (2.9)      |
| Tightness of the skin        | -2.9 (2.6)       | -2.7 (2.3)   | -3.4 (2.5)       | -3.6 (2.7)     | -0.5 (2.2)   | -3.3 (3.0)      |
| Pain                         | -0.9 (2.2)       | -0.8 (2.3)   | -0.9 (2.0)       | -0.9 (2.3)     | -0.4 (1.6)   | -1.5 (2.5)      |
| Total score                  | -7.6 (7.3)       | -7.0 (6.0)   | -9.1 (6.7)       | -10.5 (6.4)    | -1.4 (6.6)   | -8.5 (9.3)      |

| Quality of Life              | Whole Population | Chemotherapy | Targeted Therapy | Hormone Therapy | Radiotherapy | Combined Therapy |
|------------------------------|------------------|--------------|------------------|----------------|--------------|-----------------|
| DLQI score, mean (SD)        | N=317            | N=111        | N=106            | N=19           | N=29         | N=52            |
| Total score                  | -1.5 (1.9)       | -1.1 (1.1)   | -1.5 (1.2)       | -2.1 (1.2)     | -1.8 (4.0)   | -2.0 (2.5)      |

Abbreviations: DLQI, Dermatology Life Quality Index; N, number of patients for whom total score data were available; SD, standard deviation; VAS, visual analog scale. A 4-point severity scale from 0 (no signs) to 3 (severe) was used by the physician to assess each objective clinical symptom. Total score scale ranged from 0 to 9. VAS score was assessed by the patient and the scale of each symptom ranged from 0 (absent) to 10 (very severe). Total VAS score scale ranged from 0 to 40. DLQI total score scale ranged from 0 (no effect at all on patient’s life) to 30 (extremely large effect on patient’s life). p-value <0.0001, p-value <0.001, p-value <0.05

Table S3: Self-evaluation of improvement in clinical symptoms related to xerosis.

| Symptoms          | N patients | Absolutely yes | Yes | Somewhat yes | Not at all | Not relevant | Total yes (on concerned patients) |
|-------------------|------------|----------------|-----|--------------|------------|--------------|-----------------------------------|
| Pruritus          | 312        | 115 (36.9)     | 110 (35.3) | 46 (14.7) | 12 (3.8) | 29 (9.3) | 271/283 (95.8)                  |
| Desquamation      | 308        | 117 (38.0)     | 113 (36.7) | 44 (14.3) | 9 (2.9)  | 25 (8.1) | 274/283 (96.8)                  |
| Redness           | 312        | 93 (29.8)      | 88 (28.2)  | 62 (19.9)  | 15 (4.8) | 54 (17.3) | 243/258 (94.2)                  |
| Dryness           | 313        | 131 (41.9)     | 142 (45.4) | 39 (12.5)  | 1 (0.3)  | 0 (0)   | 312/313 (99.7)                  |
| Tightness         | 309        | 96 (31.1)      | 116 (37.5) | 46 (14.9)  | 10 (3.2) | 41 (13.3) | 258/268 (96.3)                  |
| Pain              | 308        | 65 (21.1)      | 79 (25.6)  | 27 (8.8)   | 19 (6.2) | 118 (38.3) | 171/190 (90.0)                  |
| Sleep disturbance | 308        | 48 (15.6)      | 68 (22.1)  | 43 (14.0)  | 24 (7.8) | 125 (40.6) | 159/183 (86.9)                  |